You are here



Barcelona, July 26, 2022. -Investment in health startups in the BioRegion of Catalonia set a new record in the first half of the year: €296 million, more than all funding secured in 2021 (€238 million). This period (January to July) was the best ever, fueled once again by venture capital, which totaled €258 million, or 87% of the capital raised, followed by the stock market, public grants and crowdequity.


francesca wuttke startup generation nen

Francesca Domenech Wuttke

CEO and Founder of Nen

PhD in Pharmacology from the Weill Cornell Graduate School of Medical Sciences (New York) and a degree in Biology and Society from Cornell University (New York). She has extensive experience in drug development and healthcare, both in the United States and Europe. She has worked at several organizations, accelerating and incubating startups, heading up European investments and leading mergers and acquisitions of medical devices and pharmaceuticals.

post blog boost 4 health

Measuring the impact of the projects: the case of Boost4Health (I)

Only a few months from completion, Boost4Health has helped over 50 startups from the BioRegion in their internationalization. Beyond measuring the number of companies or how they access new markets thanks to the grants received, this post goes a step further and provides an overview of the possible impact of the positive effect on the health of people and patients.

Diliara Lupenko, chief operating officer at Impress

Diliara Lupenko

Chief Operations Officer at Impress

She has over 15 years of experience in consulting, corporate strategy and entrepreneurship. Having worked in multinationals, she founded Impress in 2019 inspired by her own personal experience with invisible orthodontics treatment.

How can we improve healthcare innovation adoption in Catalonia? Digital health therapeutics companies respond

We get a first-hand look at the experience of Catalan digital therapeutics companies (DTx) with the healthcare system and take advantage to ask what needs to improve, in their opinion, to facilitate adoption of innovative projects like theirs.


Esther Riambau

Co-founder and CEO of Oniria Therapeutics

She holds degrees in Biology and Biochemistry and a Master in Business Administration (MBA). She is the co-founder and CEO of Oniria Therapeutics, and co-founder and board member of Gate2Brain. Her slogan? “My training in is technology transfer but my heart is in startups.”


Remote working in the BioRegion: a new reality that is here to stay?

Last March, the SARS-CoV-2 pandemic put mobility and social life on hold in most of the world, however in biotech and healthcare, things didn’t stop at all. It was just the opposite, in fact, with activity ramping up. But the pandemic has forced the sector to turn to new ways of working and, in some cases, seem they’re here to stay.